Treatment of Rosacea with Isotretinoin

Hoting, E.; Paul, Eberhard; Plewig, Gerd

doi:10.1111/j.1365-4362.1986.tb04533.x

Cited by 84 publications

(45 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14,[26][27][28] Inflammation of the lids with recurrent chalazion and inflammation of the meibomian glands may be present. Interpalpebral conjunctival hyperemia, conjunctival telangiectases, and watery or dry, irritated eyes can occur.…”

Section: Ocular Rosaceamentioning

confidence: 99%

Rosacea: I. Etiology, pathogenesis, and subtype classification

Crawford

Pelle

James

2004

Journal of the American Academy of Dermatology

452

447

View full text Add to dashboard Cite

Section: Ocular Rosaceamentioning

confidence: 99%

Rosacea: I. Etiology, pathogenesis, and subtype classification

Crawford

Pelle

James

2004

Journal of the American Academy of Dermatology

452

447

View full text Add to dashboard Cite

“…In addition, there are increasing indications that iso tretinoin may also exert an influence on the androgen receptor [33,34], From the group of acne-related disor ders, gram-negative folliculitis and severe rosacea have become absolute indications. For these two indications, the emphasis of the mechanisms of action shifts more in the direction of anti-inflammation and immunomodulation [35][36][37], While the superiority of etretinate to isotretinoin is indisputable for the chronic, plaque-like type of psoriasis, isotretinoin is definitely another alternative for the local ized and generalized pustular types [38J. The influence exerted on lymphocytes or mesenchymal cells, i.e.…”

Section: Isotretinoinmentioning

confidence: 99%

New Indications and New Retinoids

Gollnick¹

1987

Dermatology

View full text Add to dashboard Cite

In addition to well-accepted indications, etretinate has a beneficial effect in a variety of other dermatoses such as the hyperkeratotic eczema of the palms and soles, prurigo nodularis, and other nonpsoriatic, sterile, pustular eruptions. Due to its influence on dermal inflammatory processes and immunomodulation of the tissue response, etretinate is effective in cutaneous lupus erythematosus, certain bullous disorders like pemphigus herpetiformis, the persistent variant of Grover’s disease, dermatitis herpetiformis, and bullous pemphigoid. Isotretinoin is reported to be effective in cutaneous sarcoidosis, disseminated granuloma annulare, systemic sclerosis and tumors of the cutaneous appendages. New synthetic retinoids have been developed. Etretin, the main metabolite of etretinate, was shown to be effective and to have a short elimination half-life of – 50 h. Arotinoid ethyl ester and arotinoid-free carboxylic acid are effective in minimal doses 500-fold lower than etretinate. Arotinoid ethyl ester was shown not to increase serum lipids. Arotinoid ethyl sulfone is the first retinoid without bone toxicity in animal experiments. Motretinide is the ethylamide of tretinoin and is reported to be effective in the local treatment of acne. Some of the new poly-aromatic retinoids appear to have sebosuppressive, antikeratinizing and/or anti-inflammatory effects via topical application.

show abstract

“…[69][70][71][72][73] The effects of isotretinoin can be delayed in comparison with standard therapies, 46,74 although a reduction of papule counts may be evident as early as 2 weeks. 70 Irvine, Kumar, and Marks treated erythematotelangiectatic and papulopustular rosacea with either oxytetracycline (n = 6; 250 mg twice daily) or isotretinoin (n = 5; 30 mg daily) for a 2-month period.…”

Section: Isotretinoinmentioning

confidence: 99%